Mar 20, 2023 8:55am EDT MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
Mar 08, 2023 8:30am EST MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
Mar 02, 2023 8:30am EST MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
Feb 28, 2023 8:30am EST MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
Dec 06, 2022 8:00am EST ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
Nov 17, 2022 8:00am EST MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
Nov 14, 2022 8:00am EST MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
Sep 20, 2022 8:00am EDT MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
Aug 30, 2022 8:30am EDT MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound
